Docusign trades undervalued at 14x forward P/E despite a 13% drop, with strong fundamentals supporting a Buy rating.

Docusign's stock recently declined by 13%, yet it remains undervalued compared to peers, trading at a 14x forward price-to-earnings ratio versus 23x for competitors. The company's fundamentals have improved, supporting a Buy rating despite risks of continued underperformance. Current market challenges seem partially priced in, while positive factors are not fully reflected in the stock's valuation, suggesting potential for rerating and growth.